Lupin inks licensing agreement with Takeda to commercialize Vonoprazan
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The pooled prevalence of GERD in the Indian population is 15.6 %
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
EDQM has also issued a Certificate of Suitability for Allopurino
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Subscribe To Our Newsletter & Stay Updated